Ekaterina Grezina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ekaterina Grezina has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Andrey Belov
Regional Budgetary Healthcare Institution “Kursk Oblast Scientific and Clinical Center named after G. E. Ostroverkhov”, 1 Eliseeva St., Kislino Khutor, Kursky District 305524, Russia
2 shared publications - Aurika Asanova
Endocrinology Research Centre, 11 Dmitriya Ulyanova St., Moscow 117036, Russia
2 shared publications - Ekaterina Aleksandrovna Pigarova
Endocrinology Research Centre
2 shared publications - G. A. Melnichenko
Endocrinology Research Centre
2 shared publications - Irina V. Stanoevich
Endocrinology Research Centre, 11 Dmitriya Ulyanova St., Moscow 117036, Russia
2 shared publications - Ju. D. Fedorova
Faculty of Medicine, Pirogov Russian National Research Medical University, 1 Ostrovityanova St., Bldg. 6, Moscow 117997, Russia
2 shared publications
Latest Publications
- Open Access
- 23 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (6) , 956
Acromegalic Uteropathy: Specific Uterine Ultrasound Findings in Female Patients
Background/Objectives: Acromegaly is a systemic connective tissue disease driven by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess; yet, the female reproductive tract—especially the extracellular matrix (ECM)-rich cervix—has been poorly studied. We aimed to compare uterine and cervical morphology in women with acromegaly versus healthy controls and a gynecologic disease comparator, testing the hypothesis of selective cervical hypertrophy. Methods: We performed a retrospective case–control study of reproductive-age women who underwent pelvic ultrasound: acromegaly (n = 33), healthy controls (n = 45), and adenomyosis without acromegaly (n = 44). Uterine body measurements were obtained by TAUS/TVUS; cervical biometry was performed transvaginally in all cases. Volumes were estimated using the ellipsoid formula, and a uterus-to-cervix (U:C) volume ratio was calculated. Group differences were analyzed with Mann–Whitney tests and Bonferroni correction. Results: A total of 122 women were included. Uterine body length, width, AP size, and volume did not differ between acromegaly and either comparison group (all p-values non-significant). In contrast, cervical length, width, AP thickness, and volume were significantly higher in acromegaly than in healthy controls, with a corresponding reduction in the U:C volume ratio, indicating disproportionate cervical enlargement. Compared with adenomyosis, women with acromegaly again showed larger cervical width, AP thickness, and volume, together with altered U:C indices, whereas cervical length did not differ, suggesting a pattern not explained by nonspecific pelvic pathology. Conclusions: Women with acromegaly demonstrate a distinct uterine phenotype characterized by selective cervical hypertrophy with preserved uterine corpus size—an ECM-centric “acromegalic uteropathy.” This noninvasive morphometric signature may have diagnostic and procedural relevance and warrants confirmation in prospective studies.
- 23 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (6) , 956
Open AccessAcromegalic Uteropathy: Specific Uterine Ultrasound Findings in Female Patients
Background/Objectives: Acromegaly is a systemic connective tissue disease driven by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess; yet, the female reproductive tract—especially the extracellular matrix (ECM)-rich cervix—has been poorly studied. We aimed to compare uterine and cervical morphology in women with acromegaly versus healthy controls and a gynecologic disease comparator, testing the hypothesis of selective cervical hypertrophy. Methods: We performed a retrospective case–control study of reproductive-age women who underwent pelvic ultrasound: acromegaly (n = 33), healthy controls (n = 45), and adenomyosis without acromegaly (n = 44). Uterine body measurements were obtained by TAUS/TVUS; cervical biometry was performed transvaginally in all cases. Volumes were estimated using the ellipsoid formula, and a uterus-to-cervix (U:C) volume ratio was calculated. Group differences were analyzed with Mann–Whitney tests and Bonferroni correction. Results: A total of 122 women were included. Uterine body length, width, AP size, and volume did not differ between acromegaly and either comparison group (all p-values non-significant). In contrast, cervical length, width, AP thickness, and volume were significantly higher in acromegaly than in healthy controls, with a corresponding reduction in the U:C volume ratio, indicating disproportionate cervical enlargement. Compared with adenomyosis, women with acromegaly again showed larger cervical width, AP thickness, and volume, together with altered U:C indices, whereas cervical length did not differ, suggesting a pattern not explained by nonspecific pelvic pathology. Conclusions: Women with acromegaly demonstrate a distinct uterine phenotype characterized by selective cervical hypertrophy with preserved uterine corpus size—an ECM-centric “acromegalic uteropathy.” This noninvasive morphometric signature may have diagnostic and procedural relevance and warrants confirmation in prospective studies.
- Open Access
- 30 January 2026
- Published by MDPI AG in Preprints.org
Acromegalic Uteropathy: Specific Uterine Ultrasound Findings in Female Patients
Background/Objectives: Acromegaly is a systemic connective-tissue disease driven by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess, yet the female reproductive tract—especially the extracellular matrix (ECM)-rich cervix—has been poorly studied. We aimed to compare uterine and cervical morphology in women with acromegaly versus healthy controls and a gynecologic disease comparator, testing the hypothesis of selective cervical hypertrophy. Methods: We performed a retrospective case–control study of reproductive-age women who underwent pelvic ultrasound: acromegaly (n=33), healthy controls (n=45), and adenomyosis without acromegaly (n=44). Uterine body and cervical length, width, and anteroposterior (AP) dimensions were measured transvaginally/transabdominally. Volumes were estimated using the ellipsoid formula, and a uterus-to-cervix (U:C) volume ratio was calculated. Group differences were analyzed with Mann–Whitney tests and Bonferroni correction. Results: A total of 122 women were included. Uterine body length, width, AP size, and volume did not differ between acromegaly and either comparison group (all p>0.1). In contrast, cervical length, width, AP thickness, and volume were significantly higher in acromegaly than in healthy controls, with a corresponding reduction in the U:C volume ratio, indicating disproportionate cervical enlargement. Compared with adenomyosis, women with acromegaly again showed larger cervical dimensions and altered U:C indices, suggesting a pattern not explained by nonspecific pelvic pathology. Conclusions: Women with acromegaly demonstrate a distinct uterine phenotype characterized by selective cervical hypertrophy with preserved uterine corpus size—an ECM-centric “acromegalic uteropathy.” This non-invasive morphometric signature may have diagnostic and procedural relevance and warrants confirmation in prospective studies.
- 30 January 2026
- Published by MDPI AG in Preprints.org
Open AccessAcromegalic Uteropathy: Specific Uterine Ultrasound Findings in Female Patients
Background/Objectives: Acromegaly is a systemic connective-tissue disease driven by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess, yet the female reproductive tract—especially the extracellular matrix (ECM)-rich cervix—has been poorly studied. We aimed to compare uterine and cervical morphology in women with acromegaly versus healthy controls and a gynecologic disease comparator, testing the hypothesis of selective cervical hypertrophy. Methods: We performed a retrospective case–control study of reproductive-age women who underwent pelvic ultrasound: acromegaly (n=33), healthy controls (n=45), and adenomyosis without acromegaly (n=44). Uterine body and cervical length, width, and anteroposterior (AP) dimensions were measured transvaginally/transabdominally. Volumes were estimated using the ellipsoid formula, and a uterus-to-cervix (U:C) volume ratio was calculated. Group differences were analyzed with Mann–Whitney tests and Bonferroni correction. Results: A total of 122 women were included. Uterine body length, width, AP size, and volume did not differ between acromegaly and either comparison group (all p>0.1). In contrast, cervical length, width, AP thickness, and volume were significantly higher in acromegaly than in healthy controls, with a corresponding reduction in the U:C volume ratio, indicating disproportionate cervical enlargement. Compared with adenomyosis, women with acromegaly again showed larger cervical dimensions and altered U:C indices, suggesting a pattern not explained by nonspecific pelvic pathology. Conclusions: Women with acromegaly demonstrate a distinct uterine phenotype characterized by selective cervical hypertrophy with preserved uterine corpus size—an ECM-centric “acromegalic uteropathy.” This non-invasive morphometric signature may have diagnostic and procedural relevance and warrants confirmation in prospective studies.